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Abstract
Background: In humans, Mammalian Target of Rapamycin (MTOR) encodes a 300 kDa serine/ threonine protein
kinase that is ubiquitously expressed, particularly at high levels in brain. MTOR functions as an integrator of multiple
cellular processes, and in so doing either directly or indirectly regulates the phosphorylation of at least 800 proteins.
While somatic MTOR mutations have been recognized in tumors for many years, and more recently in
hemimegalencephaly, germline MTOR mutations have rarely been described.
Case presentation: We report the successful application of family-trio Diagnostic Exome Sequencing (DES) to
identify the underlying molecular etiology in two brothers with multiple neurological and developmental lesions,
and for whom previous testing was non-diagnostic. The affected brothers, who were 6 and 23 years of age at the
time of DES, presented symptoms including but not limited to mild Autism Spectrum Disorder (ASD), megalencephaly,
gross motor skill delay, cryptorchidism and bilateral iris coloboma. Importantly, we determined that each
affected brother harbored the MTOR missense alteration p.E1799K (c.5395G>A). This exact variant has been
previously identified in multiple independent human somatic cancer samples and has been shown to result
in increased MTOR activation. Further, recent independent reports describe two unrelated families in whom
p.E1799K co-segregated with megalencephaly and intellectual disability (ID); in both cases, p.E1799K was
shown to have originated due to germline mosaicism. In the case of the family reported herein, the absence
of p.E1799K in genomic DNA extracted from the blood of either parent suggests that this alteration most
likely arose due to gonadal mosaicism. Further, the p.E1799K variant exerts its effect by a gain-of-function
(GOF), autosomal dominant mechanism.
Conclusion: Herein, we describe the use of DES to uncover an activating MTOR missense alteration of
gonadal mosaic origin that is likely to be the causative mutation in two brothers who present multiple
neurological and developmental abnormalities. Our report brings the total number of families who harbor
MTOR p.E1799K in association with megalencephaly and ID to three. In each case, evidence suggests that
p.E1799K arose in the affected individuals due to gonadal mosaicism. Thus, MTOR p.E1799K can now be
classified as a pathogenic GOF mutation that causes megalencephaly and cognitive impairment in humans.
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Background
Autism spectrum disorders (ASDs) are a group of neuro-
developmental maladies marked by social/communication
impairments, repetitive behaviors, and sensory reactivity
issues [1]. Even though the molecular etiology of autism is
genetically heterogeneous, up to 10 % of cases are associ-
ated with a distinct genetic condition such as Fragile X
syndrome, tuberous sclerosis, phenylketonuria, or Rett
syndrome [2–5]. Furthermore, 20 % of autistic patients ex-
hibit macrocephaly [6]. In a number of these cases, germ-
line mutations in the tumor suppressor gene PTEN
(Phosphatase and Tensin Homologue) have been revealed
to be the underlying cause of disease [7–11]. It has been
estimated that the rate of PTEN disruption is up to 5 % in
ASD patients with macrocephaly [12].
PTEN functions as a negative regulator of the PI3K
(Phosphoinositide 3-Kinase)–AKT (AKT/Protein Kinase
B)-MTOR (Mammalian Target of Rapamycin) signaling
cascade, a simplified version of which is depicted in
Fig. 1. At the center of this pathway lies MTOR, a
300 kDa serine/threonine protein kinase encoded by the
MTOR gene, which in humans is situated on chromo-
some 1p36 [13]. By integrating upstream signals to
downstream effector molecules like ribosomal P70 S6
(S6) and ribosomal P70 S6 kinase (S6K), the PI3K-AKT-
MTOR axis serves to regulate a myriad of biological
processes including cell growth and proliferation, apop-
tosis, protein synthesis, and transcription [14]. MTOR is
known to mediate normal brain development by playing
key roles in axonal and dendritic growth, and in the es-
tablishment and maintenance of synaptic plasticity [15].
As evidenced by the association of PTEN dysfunction
with ASD and macrocephaly, hyper-activation of the
PI3K-AKT-MTOR signaling cascade is an underlying
factor for neurological disease and abnormal develop-
ment. Such ‘TORopathies’ include neurological ailments
Fig. 1 Simplified representation of the MTOR signaling network. Green arrows indicate the specific substrates shown to be phosphorylated/
over-stimulated by p.E1799K-hyperactivated MTOR kinase. Other symbols and abbreviations used: stimulatory effects ( ); inhibitory effects
( ); 4E-BP1 (Eukaryotic Translation Initiation Factor 4E-Binding Protein 1); AKT (AKT/ Protein Kinase B); MTOR (Mammalian Target of
Rapamycin); PI3K (Phosphoinositide 3-Kinase); PTEN (Phosphatase and Tensin Homolog); RAS (Rat Sarcoma Viral Oncogene Homolog); S6K (Ribosomal
P70 S6 Kinase 1); TORC1 (MTOR Complex 1); TORC2 (MTOR Complex 2) TSC1 (Tuberous Sclerosis 1); TSC2 (Tuberous Sclerosis 2)
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like focal cortical malformations (FCM), tuberous scler-
osis complex (TSC), and hemimegalencephaly, all of
which are highly associated with epilepsy [16, 17]. Fur-
thermore, hyperactivation of the MTOR axis has also
been associated with somatic cancer [18].
Although specific molecular lesions have been defined
for some TORopathies–for example, in cases where PTEN
is disrupted–in many instances it remains difficult to pin-
point the exact molecular defect due to the complexity of
the MTOR signaling network [17]. Even so, the emer-
gence of next generation sequencing (NGS) has greatly
facilitated the search for genes and pathogenic variants
that underlie neurological disease. Several recent reports
have detailed the successful use of whole exome sequen-
cing (WES) to uncover both somatic and germline activat-
ing alterations within MTOR itself. [19–23] These clinical
studies describe damaging MTOR alleles in unrelated pro-
bands who present overlapping neurological symptoms
and brain defects [19–23]. In a recent cancer study, Grabi-
ner and colleagues accessed publicly available sequencing
data from tumor samples to uncover 33 MTOR alterations
that conferred hyperactivation of the MTOR signaling
pathway within cancer cells. These alterations clustered
around six distinct regions in the C-terminal half of the
protein [18].
Herein, we present the clinical and genetic investi-
gation of two brothers affected with macrocephaly
and ASD. Diagnostic Exome Sequencing (DES) identi-
fied a GOF MTOR alteration, p.E1799K, to be the
causative mutation in this family. Co-segregation and
short tandem repeat (STR) analyses revealed that




Table 1 lists the major clinical features displayed by the
proband and his brother, as well as the features of add-
itional patients who harbor MTOR p.E1799K but who
are unrelated to the family described herein. The pro-
band, who presented to medical genetics clinic at age 3
with macrocephaly, bilateral iris colobomas and gross
motor delay, had a mildly unusual appearance, which
was primarily due to macrocephaly with a prominent
forehead (Fig. 2a, left panels). The proband was the
product of an uncomplicated pregnancy and was large
for his gestational age, with a weight of 2950 g (97 %) at
35 weeks; birth head circumference was not recorded.
Since infancy, his linear growth and weight have been
normal; however, macrocephaly was noted by 6 months,
which prompted a head ultrasound. The result showed
no evidence of hydrocephalus. Since 3 years of age, the
proband’s head growth has been tracking parallel to, and
6 standard deviations above the mean. Investigation by
magnetic resonance imaging revealed megalencephaly.
Bilateral iris colobomas with normal posterior poles
were noted at birth, and the proband wears glasses for
strabismus. During infancy, he displayed hyperinsuline-
mia, which was managed through frequent feedings and
administration of diazoxide. He continues to display
asthma, as well as persistent food allergies that manifest
through gastrointestinal and cutaneous symptoms.
Table 1 Clinical Findings Associated with MTOR E1799Ka
Proband Sibling Baynam 1 Baynam 2 Baynam 3
Lgab + + - + +
Postnatal height/
weight
Normal Normal Normal Normal Unknown
Macrocephaly +5SD +5SD >+3SD >+3SD >+3SD






Small pons & medulla Hypogenesis of corpus
callosum
Gray matter heterotopia
Intellectual disability Mild disability/autism Moderate disability/autism Hyperactive/speech delay Marked global delay Marked global delay
Seizures - - + + +
Eye Iris coloboma Iris coloboma - - -
Noonan-like face - - + + +
Small chest/large
abdomen
- - + + +
aThis table does not include the case of an additional patient who harbors MTOR E1799K (Ghahramani et al., ACMG 2015) due to lack of access to the patient's
detailed clinical information
bLarge for gestational age
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The proband required surgery for undescended testes
and an inguinal hernia. He did not display any unusual
skin pigmentation in the genital area. Further, he has
never displayed seizures. Initially hypotonic with de-
layed gross motor milestones, the proband walked at
18 months but remained somewhat hypotonic. His
early language milestones appeared normal, but he sub-
sequently exhibited significant social delays that were
interpreted as mild ASD. Testing at age 7 revealed that
his overall cognitive ability rated in the mildly impaired
range. Previous genetic testing, which included PTEN
sequencing and chromosomal microarray analysis, did
not reveal any molecular abnormalities.
The proband’s older brother, who had previously dis-
played clinical features including macrocephaly, unilat-
eral iris coloboma and autism, presented an unusual
appearance, mainly due to severe macrocephaly, a prom-
inent forehead, and deep set eyes surrounded by dark
circles (Fig. 2a, right panels). The product of an uncom-
plicated pregnancy, the elder brother was born at
36 weeks and was large for his gestational age, with a
weight of 3400 g (>97 %) and head circumference of
36 cm (>97 %). Although his subsequent linear growth
and weight were normal, his macrocephaly nevertheless
persisted. Since age 2, his head grew parallel to the norm
but tracked 6 standard deviations above the mean,
reaching an adult circumference of 65 cm. MRI scans
revealed only megalencephaly. Although he is lactose
intolerant and displays mild asthma, he does not display
the severe allergies suffered by the proband. Unilateral
iris coloboma was noted at birth and he has required
several surgeries for strabismus; otherwise, his vision has
been normal. In addition, he underwent surgery for
undescended testes. The older brother has never had
seizures; however, he was hypotonic and displayed
significant delays in both speech and motor skills. Fur-
thermore, repeated testing during childhood showed that
he presented mild to moderate intellectual disability. His
speech and social skills remained significantly below
other developmental metrics, and as a teenager he was
diagnosed with autism. Karyotype and Fragile–X test
results were normal.
The brothers’ parents, who are healthy and non-
consanguineous, possess normal intelligence, regular
head circumference, and normal eyes. The father is of
Norwegian, German and Bohemian descent, while the
mother is of mixed European and Japanese ancestry. It
should be noted that in addition to conceiving/giving
birth to the proband and his brother, the parents/
mother suffered a miscarriage due to trisomy 18. Fur-
thermore, a maternal nephew displays mild autism des-
pite having normal intelligence, and the paternal great
Fig. 2 Clinical presentation and co-segregation analysis. a) Photographs of the proband (left column) and his affected brother (right column) at different
ages. b) Familial co-segregation/ Sanger sequencing analyses indicate that the affected brothers are heterozygous for MTOR c.5395G>A, p.E1799K (red
arrows); in contrast, both parents are homozygous for the wild type allele. These results strongly suggest that c.5395G>A (p.E1799K) arose due to gonadal
mosaicism in one of the parents. Chromatograms are shown beneath each member of the pedigree. Note that ‘+’ indicates whole exome sequencing
was performed, while open shapes represent unaffected family members; the black shapes represent the affected brothers
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grandmother was stated to have an iris coloboma,
though no records are available to confirm this. No one
else in the family has been reported to have macro-
cephaly or significant cognitive disability.
Due to the proband’s unique combination of symptoms,
that is, macrocephaly and mild ASD, as well as normal
PTEN sequencing results and normal comparative gen-
omic hybridization (CGH) array results, DES was under-
taken at age 6 years. We performed family trio-DES on
genomic DNA (gDNA) isolated from the blood leukocytes
of the proband, mother and brother. We then analyzed
the resultant NGS data through bioinformatic filtering, in-
heritance modeling and finally, expert medical review. In
so doing, we discovered that the likely molecular lesion




All research described in this case report was con-
ducted in accordance with the World Medical Associ-
ation Declaration of Helsinki. Furthermore, the
clinical information presented herein was collected
during the routine clinical care of a patient in the
United States; thus, in accordance with US law, this
study is exempt from Institutional Research Board ap-
proval. In order to perform the variant filtering and
co-segregation analysis that are integral to the exome
trio sequencing test, it is necessary to include relevant
family member samples in the sequencing trio. This
format, which is currently a standard approach for
clinical exome testing, is explicitly stated on the test
requisition form. The mother of the patient approved
the inclusion of all family members in the test. Fur-
ther, all subjects provided signed, written informed
consent to participate in this study. Written informed
consent from the parents of the 6 year-old proband, as
well as the written informed consent from the 23 year-
old brother have been obtained for the publication of
this case report and any accompanying images.
Diagnostic exome sequencing (DES)
Genomic DNA was isolated from whole blood ex-
tracted from each family member utilizing the QIA-
symphony gDNA extraction system (Qiagen, Hilden,
Germany). Samples were prepared using either the
SureSelect Target Enrichment System (Agilent Tech-
nologies, Santa Clara, CA) [24] or the SeqCap EZ
VCRome 2.0 system (Roche NimbleGen, Madison,
WI) [25]. Briefly, each DNA sample was sheared,
blunt-end repaired, and ligated to indexed adapters.
Utilizing solution-based hybridization with oligo-
nucleotide probes, the coding exons and neighboring
intronic sequence of each genome were enriched,
while off-target sequences were washed away. The result-
ant enriched exome libraries were applied to the solid
surface flow cell of an Illumina HiSeq 2000 sequencer
(Illumina, San Diego, CA) for clonal amplification and
sequencing using paired-end, 100-cycle chemistry.
NGS data analysis
The acquisition and processing of data, alignment of
sequence to Genome Reference Consortium Human
genome build 37 (GRCh37), and bioinformatic filtering
were performed as described in Farwell et al., 2014 [26].
Initial data processing/base calling, including extraction
of cluster intensities, was performed using RTA 1.12.4
(HiSeq Control Software 1.4.5). The sequence quality
filtering script was executed using Illumina CASAVA
software (ver 1.8.2, Illumina, Hayward, CA). Sequencing
run metrics, including data yield (Mbases), %PF (pass-fil-
ter), number of reads, per cent of raw clusters per lane,
and quality scores, were recorded in the Demultiplex_-
Stats.htm file and verified to surpass quality thresholds.
Sequences were aligned to the human genome reference
sequence GRCh37 and variant calls were generated
using CASAVA and Pindel [27]. All exonic sequence and
a minimum of 2 bases of flanking intronic sequence
were analyzed. Data analysis focused on nonsense vari-
ants, small insertions and deletions, canonical splice site
alterations, and non-synonymous missense alterations.
Previously described gene mutations and polymorphisms
were screened using resources that included the Human
Gene Mutation Database Professional 2011.3 (HGMD
2011.3) [28], the Single Nucleotide Polymorphism data-
base (dbSNP) [29], 1000 genomes [30], HapMap data
[31] and NCBI resources such as PubMed. Importantly,
the in silico filtering pipeline protected all variants anno-
tated within the HGMD 2011.3 [28] and/ or the Online
Mendelian Inheritance in Man (OMIM) database. Step-
wise filtering included the removal of common Single
Nucleotide Polymorphisms (SNPs), intergenic and 3′/5′
UTR (untranslated region) variants, non-splice-related
intronic variants, and synonymous variants. Remaining
variants were filtered for family history using models of
inheritance. For every filtered variant, Ambry Variant
Analyzer (AVA) was utilized to annotate the data, which
included nucleotide and amino acid conservation; bio-
chemical nature of the amino acid substitution; population
frequency as tabulated in the ESP and 1000 genomes [30]
databases; and finally, the impact of the nucleotide substi-
tution on protein function, as predicted by the in silico
modeling algorithms PolyPhen [32] and SIFT [33]. Im-
portantly, each candidate alteration was reviewed by a
molecular geneticist in order to assess the likelihood of
pathogenicity. NGS alignments were viewed using the
Integrative Genomics Viewer (IGV) software (Broad
Institute, Cambridge, MA) [34].
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Microsatellite analysis
Short tandem repeat (STR) analysis was performed on
each family member. Briefly, seven independent loci sit-
uated on separate chromosomes were amplified with
fluorescently labeled primers and the resultant products
electrophoresed on an ABI3730 DNA sequencer.
Co-segregation analysis
Candidate alterations identified as potentially causative
were confirmed using automated fluorescence dideoxy
Sanger sequencing. Co-segregation analysis was per-
formed on each available family member. Target spe-
cific primers were designed to include 5′ terminal
sense and antisense sequencing tags. The gene-specific
moieties of the primers were designed with the aid of
PrimerZ [35]; oligonucleotides were synthesized by In-
tegrated DNA Technologies (Coralville, IA) and se-
quencing was performed on an automated ABI3730
DNA sequencer (Life Technologies, Carlsbad, CA) ac-
cording to standard procedures.
Computational-structural modeling
The crystal structure of MTOR (PDB:4JSP) was used to
model the location of the observed variant, MTOR
p.E1799 [36]. Visualization of the local environment
structure and overlap of the variant amino acid were
performed in PyMOL (The Open Source PyMOL Mo-
lecular Graphics System, Version 1.7.x Schrödinger, LLC).
Results and discussion
Family trio DES coupled to bioinformatic analysis
identifies MTOR p.E1799K as the likely genetic lesion
Exome sequencing of the family trio (proband, mother
and brother) resulted in an average of 6.82 Gb being col-
lected per sample. The average exome read depth/mean
fold-coverage was 65.64 per sample, with an average of
93.13 % of bases covered at least 10-fold. On average,
81 % of bases had a quality score of Q30 or higher. Over-
all, the average base-call mean quality score for the family
trio exceeded Q32 (Additional file 1: Table S1). Stepwise
filtering of common SNPs, intergenic and 3′/5′ UTR vari-
ants, non-splice-related intronic variants, and synonymous
variants resulted in approximately 11,000 variants being
associated with each trio member (Additional file 2:
Table S2). Subsequent filtering based on family history
and inheritance modeling (autosomal dominant/recessive,
X-linked dominant/recessive, and Y-linked) within the trio
narrowed the list of candidates to 36 genes and 42
unique alterations (Additional file 3: Table S3). After
manual review of each alteration in order to rule out
sequencing artifacts and polymorphisms, followed by
expert medical interpretation to rule out genes lacking
clinical overlap, the list of candidates was narrowed to 2
genes, each with a unique alteration. These notable can-
didate genes, along with their respective alterations and
corresponding in silico prediction scores, are presented
in Table 2.
One of the candidates under consideration was an
Oligophrenin-1 (OPHN1) variant of uncertain signifi-
cance (VUS), c.2363G>A (p.R788Q). Both the proband
and his brother were hemizygous for this VUS, while
their mother was heterozygous. OPHN1 disruption has
been shown to cause syndromic X-linked intellectual
disability with cerebellar hypoplasia in affected individ-
uals, and it also results in distinctive facial features [37].
Although one brother’s facial appearance demonstrated
some similarity to the faces of OPHN1-mutated individ-
uals, the overall set of traits displayed by the family
herein is incongruous with the notion that the OPHN1
VUS is the underlying cause of disease. For instance,
both affected brothers display macrocephaly, which has
not been previously attributed to mutations in OPHN1.
Moreover, the lack of the key clinical finding of cerebel-
lar hypoplasia in the affected brothers, as well as the
absence of the usual carrier phenotype in the mother
makes OPHN1 an unlikely molecular candidate for
disease. We therefore determined that the MTOR alter-
ation c.5395G>A (p.E1799K), which is carried by both
affected brothers but absent in the mother (Table 3),
displayed sufficient clinical overlap with the proband’s
phenotype to warrant further investigation/confirmation.
Sanger sequencing confirms that p.E1799K co-segregates
with disease in the family
As indicated by the red arrows shown in the lower two
chromatograms of Fig. 2b, automated fluorescent dideoxy
sequencing of gDNA extracted from family member blood
samples confirmed the presence of the MTOR alteration
c.5395G>A (p.E1799K) in the proband and his affected
brother. In contrast, c.5395G>A (p.E1799K) was not
Table 2 Notable candidate genes/alterations














Oligophrenin-1 (OPHN1) NM_002547 ChrX:67272394C>T c.2363G>A
p.R788Q




aGenomic coordinates correspond to GRCh37/hg19. Note that at the genomic level, both the MTOR and the OLPHN1 variants are notated by their complementary
bases. This is due to the fact that each gene is encoded by the minus strand of its respective chromosome
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detected in the peripheral blood mononuclear cell
(PBMC) gDNA of either parent (Fig. 2b, upper chromato-
grams). Because the STR results are consistent with the
reported familial relationships, these co-segregation data
strongly suggest that the MTOR variant c.5395G>A
(p.E1799K) originated as a consequence of gonadal mosai-
cism in one of the parents.
MTOR dysfunction is concordant with the patients'
phenotype
Overstimulation of the MTOR signaling network, as well
as hyperactivation of MTOR itself have been shown to
cause symptoms that overlap those displayed by the pro-
band and his brother, namely macrocephaly and ASD
[7–11, 23]. In humans, MTOR is expressed in every tis-
sue of the body and is highly expressed in brain, where
it plays important roles in axonal and dendritic growth,
as well as in synaptic plasticity [15]. It is understood that
the PI3K-AKT-MTOR signaling pathway plays a key role
in mammalian growth and development via its ability to
regulate protein translation (Fig. 1). Emerging evidence
suggests that the MTOR axis regulates brain development
by not simply acting as an ‘on/off ’ switch that promotes
beneficial protein synthesis, but rather by functioning as a
valve that modulates translational rates during distinct
temporal windows. Thus, if excessive protein synthesis
occurs at the wrong time, it can result in significant defi-
cits in synaptic plasticity and behavior [15].
Although there is ample evidence that other genes in
the MTOR pathway, particularly PTEN, cause neurode-
velopmental abnormalities including macrocephaly and
autism, the first report of a pathogenic mutation in
MTOR itself was a mosaic somatic mutation limited to
the affected brain tissue of a child with hemimegalence-
phaly [19]. Subsequently, non-mosaic germline MTOR
mutations were reported in two unrelated children with
seizures and developmental delay, one of whom had
documented megalencephaly and callosal dysgenesis
[20, 21]. Recently, Baynam and colleagues reported
three maternal half-siblings of Aboriginal Australian
heritage who presented with megalencephaly, develop-
mental delay, and epilepsy (Table 1). The affected indi-
viduals, who are unrelated to the family in this report,
share the same germline activating MTOR alteration as
that harbored by the affected brothers described herein:
p.E1799K (c.5395G>A) [22]. The authors showed that
the alteration was not present in the blood of the clinic-
ally normal mother and, as in the case of our proband
and his affected brother, p.E1799K (c.5395G>A) was
postulated to have arisen due to parental gonadal mo-
saicism [22]. Assays performed on stimulated PBMCs
from one of the affected half-sisters revealed that
MTOR activity was upregulated in her cells; moreover,
this increase in activity could be inhibited/rescued back to
normal levels through treatment with Rapamycin [22].
Emerging evidence indicates that altered MTOR activity
may be associated with allergic reactions that are capable
of triggering neuropathology. Because PTEN is an inhibi-
tor of the PI3K-AKT-MTOR signaling cascade, loss-of-
function (LOF) PTEN mutations result in increased
MTOR activity, which in turn potentiates inflammation
through 1) microglial and mast cell proliferation [38, 39],
and 2) mast cell chemotaxis and activation [40, 41]. Theo-
harides et al. proposed a model in which children with
hyperactivation of the MTOR pathway have a lower
threshold for brain mast cell stimulation and are thus
more sensitive to triggers like allergens, immune factors,
neuro-hormones, stress and toxins [42]. In support of this
model, the hormone Neurotensin (NT), which is secreted
by the hypothalamus and functions as a stimulator of
brain mast cells, is detected at increased levels in the
serum of autistic children [43].
While the relationship between our patients’ colobomas
and their MTOR mutation remains speculative, it is clear
that the PI3K-AKT-MTOR pathway affects eye develop-
ment. Most notably, Rieger anomaly is a cardinal feature
of SHORT (Short Stature, Hyperextensibility, Hernia,
Ocular Depression, Rieger Anomaly, and Teething Delay)
syndrome, which is caused by heterozygous Phos-
phatidylinositol 3-Kinase, Regulatory Subunit 1 (PIK3R1)
mutations [44]. Cataracts are also an occasional feature of
PTEN hamartoma syndrome [45].
The MTOR variant p.E1799K is a GOF pathogenic mutation
The alteration p.E1799K, which was originally identified in
multiple somatic tumor samples, has been empirically
shown to cause hyperactivation of MTOR [18]. Interest-
ingly, in HEK293 cells, p.E1799K selectively increases
MTOR kinase activity towards the substrates AKT/ Protein
Kinase B (AKT) and 4E-Binding Protein 1 (4E-BP1), but
exerts minimal effect on MTOR kinase activity towards
ribosomal P70 S6 Kinase 1 (S6K1) [18]. As illustrated in
Fig. 1, increased phosphorylation of 4E-PB1 and AKT by
TORC1 and TORC2, respectively, triggers increased pro-
tein synthesis. Moreover, constitutive or heightened MTOR
activation has the potential to decouple and/or alter the
manner in which the PI3K-AKT-MTOR signaling axis
Table 3 Family trio DES identifies the MTOR alteration p.E1799K
(c.5395G>A) in the proband and affected brother
Nucleotidesa Proband Brother Mother
Reference C 53.23% (33/62) 52.63% (20/38) 100.00% (31/31)
Mutation T 46.77% (29/62) 47.37% (18/38) 0.00% (0/31)
Q Score 220 148 119
aThe variant is notated as C>T by the alignment software because the MTOR
gene is situated on the minus strand of chromosome 1. For each trio member,
the percentage of reads is followed in brackets by the fraction of wt or variant
reads over the total number of reads
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responds to neurotransmitters and external growth and de-
velopment cues that exert their effects through neuronal
cell surface receptor binding. Further support for the no-
tion that increased MTOR activity is the mutational mech-
anism underlying neurological disease in the proband and
his affected brother comes from the fact that homozygous
LOF genotypes are tolerated in the healthy population [46].
As shown in Fig. 3a, p.E1799K is situated in the FAT
(FRAP, ATM, TRRAP) domain of MTOR. This domain
adopts a c-shaped α solenoid structure that clamps
onto the kinase domain (KD) of the enzyme and serves to
negatively regulate MTOR activity [36]. Utilizing the
MTOR crystal structure as a basis [36], we interpreted the
mechanism by which p.E1799K leads to the hyperacti-
vation of MTOR kinase. Glutamic acid 1799 (E1799),
which is spatially positioned at the MTOR FAT-kinase
domain interface, is directed towards Arginine 2505
(R2505), which is situated on the kinase side of this
boundary (Fig. 3c). Due to their proximity, E1799 and
R2505 likely interact through local electrostatic forces
(<8 Å E1799 Oε2 – R2505 Nε), and this interaction
contributes to the stringent repression of MTOR kin-
ase activity by the FAT domain. We propose that the
substitution of lysine for glutamic acid (Fig. 3c, white
and magenta sticks, respectively), disrupts this electro-
static interaction and thereby destabilizes the local
FAT-kinase environment to the point that the enzyme
is shifted to a more active state. In fact, a mechanism
similar to this has been shown to underlie the widely
studied and structurally adjacent MTOR activating
mutation, p.E2419K (Fig. 3c) [36, 47]. In this particular
case, the substitution eliminates the E2419/R1905 salt
bridge (not shown) that is normally present at the
FAT-kinase interface. The loss of the salt bridge in
turn reduces the negative regulation exerted by the
FAT clamp on the KD, which results in increased kin-
ase activity [36, 47]. Of therapeutic import is the fact
that cancer derived cell lines and xenografts that carry
the MTOR p.E1799K variant are hyper-responsive to
Rapamycin treatment [18].
In support of the notion that MTOR p.E1799K is a
pathogenic mutation that causes neurological disease
in humans, Ghahramani and colleagues recently re-
ported the same MTOR activating variant, p.E1799K,
in an unrelated proband who displayed major clinical
symptoms that were almost identical to those of the
Fig. 3 E1799K is a pathogenic activating mutation. a) Location of p.E1799K in relation to the domain/ structural organization of MTOR. Structural
elements shown are the two groups of HEAT (Huntington Elongation Factor 3, A Subunit of PP2A TOR1) repeats; the FAT (FKBP12-Rapamycin-
Associated Protein/TOR, Ataxia-Telangiectasia, Transactivation/ Transformation Domain-Associated Protein) domain; the FRB (FKBP12-Rapamycin
Binding) domain; the KIN (Kinase) domain; and the terminal FATC (FAT C-Terminal) domain. b) The conservation plot reveals that E1799 (black
rectangle) is evolutionarily conserved across vertebrates, which suggests that this amino acid plays an essential role for the normal function of
MTOR kinase. c) A 3D schematic of the local environment surrounding the FAT-kinase domain interface that illustrates the mechanism by which
p.E1799K causes hyperactivation of MTOR kinase. The FAT domain is represented in green while the kinase domain is peach-colored. Highlighted
residues include E1799 (magenta stick), K1799 (white stick) and the activating residues described in the text: E2419, R1905 and R2505 (represented
as sticks colored according to the domain in which they reside)
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brothers’ in our report: macrocephaly and intellectual
disability. Ghahramani’s group demonstrated that the
p.E1799K mutation in their proband originated as a
de novo germline event [23].
Additional evidence for the pathogenicity of MTOR
p.E1799K comes from the fact that this variant is not
present in the healthy human population. For instance,
the following databases of human genetic variation
make no reference of healthy individuals who harbor
MTOR p.E1799K: the Exome Aggregation Consortium
(ExAC), dbSNP, the 1000 Genomes database, and the
Exome Sequencing Project (ESP) [29, 46, 48].
A number of independent clinical studies have docu-
mented patients who harbor causative MTOR missense
variants and who present neurological and develop-
mental symptoms that overlap those of the affected
brothers in our study. For example, in a 2012 report,
Lee et al. detailed a 5 year-old boy who suffered from
seizures and whose brain displayed hemimegalence-
phaly (HME). Following lateral hemispherectomy,
whole exome sequencing (WES) was performed on the
patient’s excised brain tissue, as well as on his PBMCs.
WES revealed that the proband harbored the somatic
MTOR alteration p.C1483Y in his affected brain re-
gions, but neither in his unaffected brain areas nor his
PBMCs. Moreover, immunostaining revealed that the
alteration in question resulted in hyperactivation of
MTOR signaling. Since surgery, the patient has
remained symptom-free. These results strongly suggest
that the MTOR alteration p.C1483Y caused the pa-
tient’s symptoms [19]. Interestingly, a de novo germline
MTOR alteration at the same position, p.C1483F, was
identified in a 17-month old girl who displayed mega-
lencephaly and intractable seizures [49]. These data are
highly suggestive that cysteine 1483 plays an essential
role for the maintenance of normal MTOR activity;
moreover, substitution of p.C1483 for either isoleucine
or phenylalanine potentiates the development of neuro-
logical disease in humans.
Other germline MTOR alterations have been reported
in patients with epilepsy. For example, the de novo
MTOR missense variant p.M1595I was detected in a
non-verbal 18 month-old male proband who displayed
infantile spasms, myoclonic seizures, and global develop-
mental delay. Although no functional assays were under-
taken in this case, multiple in silico models predicted the
variant to be deleterious to normal protein function [20].
Because MTOR p.E1799K has been documented to be
associated with overlapping neurological and develop-
mental symptoms in independent families, and because
it has been empirically demonstrated to cause hyperactiva-
tion of MTOR kinase, we propose that this variant is a
pathogenic mutation that has the capacity to cause
megalencephaly and neurological dysfunction in humans.
Conclusions
Herein, we demonstrate that the MTOR missense vari-
ant p.E1799K is a pathogenic mutation that results in
hyperactivation of MTOR kinase activity and causes
megalencephaly/ macrocephaly and neurological impair-
ment in humans. We demonstrate that p.E1799K exerts
its effects on the developing brain by A) causing in-
creased protein synthesis that is either exaggerated or
decoupled from normal development cues during key
temporal windows, and by B) potentially causing inflam-
mation/ allergic reactions in the brain that could po-
tentiate the development of focal lesions. It is of interest
that both affected brothers in this study suffer from al-
lergies. Finally, we suggest that because cells which carry
the MTOR p.E1799K mutation are hyper-responsive to
Rapamycin, treatment with this drug during post-natal de-
velopment may prove beneficial in alleviating the craniofa-
cial and neurological symptoms that develop in children
who harbor hyper-activating MTOR mutations. Pre-
clinical and clinical trials will be necessary to bear out this
notion.
Consent
The family described in this report has provided us with
their written consent to have their clinical histories and
photographs published.
Additional files
Additional file 1: Table S1. Illumina Hiseq Run Metrics for family trio.
(PPTX 75.6 kb)
Additional file 2: Table S2. Bioinformatic Variant Filtering. (PPTX 54.9 kb)
Additional file 3: Table S3. Variant Filtering Based on Inheritance
Modeling & Interpretation. (PPTX 66.7 kb)
Abbreviations
4E-BP1 AKT: Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 AKT/
Protein Kinase B; ASD: Autism Spectrum Disorder; AVA: Ambry Variant
Analyzer; CGH: Comparative Genomic Hybridization; dbSNP: Database of
Single Nucleotide Polymorphism; DES: Diagnostic Exome Sequencing;
ESP: Exome Sequencing Project; ExAC: Exome Aggregation Consortium;
FAT: FKBP12-Rapamycin-Associated Protein/ TOR, Ataxia-Telangiectasia,
Transactivation/ Transformation Domain-Associated Protein; FATC: FAT
C-Terminal; FCM: Focal Cortical Malformation; FRB: FKBP12-Rapamycin
Binding; gDNA: Genomic DNA; GOF: Gain-of-Function; GRCh37: Genome
Reference Consortium Human Genome Build 37; HEAT: Huntington
Elongation Factor 3, A Subunit of PP2A TOR1; HGMD 2011.3: Human Gene
Mutation Database Professional 2011.3; ID: Intellectual Disability; KD: Kinase
Domain; KIN: Kinase Domain; LOF: Loss-of-Function; MTOR: Mammalian
Target of Rapamycin; NGS: Next Generation Sequencing; NT: Neurotensin;
OMIM: Online Mendelian Inheritance in Man; OPHN1: Oligophrenin-1;
PBMC: Peripheral Blood Mononuclear Cell; PI3K: Phosphoinositide 3-Kinase;
PIK3R1: Phosphatidylinositol 3-Kinase, Regulatory Subunit 1;
PTEN: Phosphatase and Tensin Homologue; RAS: Rat Sarcoma Viral
Oncogene Homolog; S6: Ribosomal P70 S6; S6K: Ribosomal P70 S6 Kinase;
SHORT: Short Stature, Hyperextensibility, Hernia, Ocular Depression, Rieger
Anomaly, and Teething Delay; SNP: Single Nucleotide Polymorphism;
STR: Short Tandem Repeat; TORC1: MTOR Complex 1; TORC2: MTOR Complex
2; TSC: Tuberous Sclerosis Complex; UTR: Untranslated Region; VUS: Variant of
Uncertain Significance; WES: Whole Exome Sequencing.
Mroske et al. BMC Medical Genetics  (2015) 16:102 Page 9 of 11
Competing interests
EM and KR declare they have no competing interests. The remaining authors
are employed by Ambry Genetics Corp., which is a for-profit clinical testing
company that specializes in helping clinicians and patients identify the cause
of genetic illness.
Authors’ contributions
EM and KR carried out the clinical evaluation and provided the clinical
genetics consultation to the patient. CM, ZP, and ST conceived of and
coordinated the study. CM, DNS, RH, HL, and RMB analyzed and interpreted
the data. CM, RH, ZP, and ST drafted the manuscript. KR, DNS, RMB, and EM
critically revised the final manuscript. All authors read and approved the final
version of the manuscript.
Author information
EM is a board certified clinical geneticist. RMB and ST are board certified
clinical molecular geneticists. KR and ZP are licensed genetic counselors.
CM and DNS are clinical genomics scientists and RH is a structural
biologist.
Acknowledgements
We are grateful to the patients and family members for giving us permission
to publish their clinical data in this report.
Author details
1Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA. 2Marshfield Clinic
Research Foundation, Marshfield, WI 54449, USA.
Received: 3 July 2015 Accepted: 3 October 2015
References
1. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
2. Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a
heterogeneous disorder. Nat Rev Genet. 2001;2(12):943–55.
3. Smalley SL, Asarnow RF, Spence MA. Autism and genetics. A decade of
research. Arch Gen Psychiatry. 1988;45(10):953–61.
4. Talebizadeh Z, Bittel DC, Miles JH, Takahashi N, Wang CH, Kibiryeva N, et al.
No association between HOXA1 and HOXB1 genes and autism spectrum
disorders (ASD). J Med Genet. 2002;39(11):e70.
5. Yonan AL, Alarcon M, Cheng R, Magnusson PK, Spence SJ, Palmer AA, et al.
A genomewide screen of 345 families for autism-susceptibility loci.
Am J Hum Genet. 2003;73(4):886–97.
6. Fombonne E, Roge B, Claverie J, Courty S, Fremolle J. Microcephaly and
macrocephaly in autism. J Autism Dev Disord. 1999;29(2):113–9.
7. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic
criteria. J Med Genet. 2000;37(11):828–30.
8. Hanssen AM, Fryns JP. Cowden syndrome. J Med Genet. 1995;32(2):117–9.
9. Reardon W, Zhou XP, Eng C. A novel germline mutation of the PTEN gene
in a patient with macrocephaly, ventricular dilatation, and features of VATER
association. J Med Genet. 2001;38(12):820–3.
10. Goffin A, Hoefsloot LH, Bosgoed E, Swillen A, Fryns JP. PTEN mutation in a
family with Cowden syndrome and autism. Am J Med Genet. 2001;105(6):521–4.
11. Zori RT, Marsh DJ, Graham GE, Marliss EB, Eng C. Germline PTEN mutation in
a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome.
Am J Med Genet. 1998;80(4):399–402.
12. Schaefer GB, Mendelsohn NJ, Professional P, Guidelines C. Clinical genetics
evaluation in identifying the etiology of autism spectrum disorders: 2013
guideline revisions. Genet Med. 2013;15(5):399–407.
13. Moore PA, Rosen CA, Carter KC. Assignment of the human FKBP12-
rapamycin-associated protein (FRAP) gene to chromosome 1p36 by
fluorescence in situ hybridization. Genomics. 1996;33(2):331–2.
14. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev.
2004;18(16):1926–45.
15. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory
and disease. Trends Neurosci. 2010;33(2):67–75.
16. Crino PB. Focal brain malformations: a spectrum of disorders along the
mTOR cascade. Novartis Found Symp. 2007;288:260–72. discussion 272–281.
17. Wong M, Crino PB: mTOR and Epileptogenesis in Developmental Brain
Malformations. In: Jasper’s Basic Mechanisms of the Epilepsies, Fourth
Edition. Edited by Noebels JL, Avoli M, Rogawski MA, Olsen RW,
Delgado-Escueta AV, 4th edn. Bethesda (MD); 2012.
18. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. A diverse
array of cancer-associated MTOR mutations are hyperactivating and can
predict rapamycin sensitivity. Cancer Discov. 2014;4(5):554–63.
19. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, et al. De
novo somatic mutations in components of the PI3K-AKT3-mTOR pathway
cause hemimegalencephaly. Nat Genet. 2012;44(8):941–5.
20. Epi KC, Epilepsy Phenome/Genome P, Allen AS, Berkovic SF, Cossette P,
Delanty N, Dlugos D, et al. De novo mutations in epileptic encephalopathies.
Nature. 2013;501(7466):217–21.
21. Soden S, Saunders CJ, Willig LK, FArrow EG, Smith LD, Petrikin JE, et al.
Effectiveness of exome and genome sequencing guided by acuity of illness for
diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6(265):265ra168.
22. Baynam G, Overkov A, Davis M, Mina K, Schofield L, Allcock R, et al. A
germline MTOR mutation in Aboriginal Australian siblings with intellectual
disability, dysmorphism, macrocephaly, and small thoraces. Am J Med
Genet A. 2015;167(7):1659–67.
23. Ghahramani N, Klein S, Ghahremani S, Lee H, Strom S, Deignan J, et al.
Activating Mutations in mTOR Cause Human Overgrowth Associated with
Macrocephaly, Intellectual Disability, and Distinct Dysmorphic Features. In:
ACMG Annual Clinical Genetics Meeting. Salt Lake City: American College of
Medical Genetics and Genomics; 2015.
24. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, et al.
Solution hybrid selection with ultra-long oligonucleotides for massively
parallel targeted sequencing. Nat Biotechnol. 2009;27(2):182–9.
25. Bainbridge MN, Wang M, Burgess DL, Kovar C, Rodesch MJ, D'Ascenzo M,
Kitzman J, Wu YQ, Newsham I, Richmond TA, et al. Whole exome capture in
solution with 3 Gbp of data. Genome Biol. 11(6):R62. http://www.
genomebiology.com.
26. Farwell KD, Shahmirzadi L, El-Khechen D, Powis Z, Chao EC, Tippin Davis B,
Baxter RM, Zeng W, Mroske C, Parra MC et al.: Enhanced utility of family-
centered diagnostic exome sequencing with inheritance model–based
analysis: results from 500 unselected families with undiagnosed genetic
conditions. Genet Med 2014:1–9
27. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth
approach to detect break points of large deletions and medium sized
insertions from paired-end short reads. Bioinformatics. 2009;25(21):2865–71.
28. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, et al. The
Human Gene Mutation Database: 2008 update. Genome Med. 2009;1(1):13.
29. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al.
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res.
2001;29(1):308–11.
30. 1000 Genomes Project C. A map of human genome variation from
population-scale sequencing. Nature. 2010;467(7319):1061–73.
31. International HapMap C. The International HapMap Project. Nature.
2003;426(6968):789–96.
32. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
et al. A method and server for predicting damaging missense mutations.
Nat Methods. 2010;7(4):248–9.
33. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous
variants on protein function using the SIFT algorithm. Nat Protoc.
2009;4(7):1073–81.
34. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G,
et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.
35. Tsai MF, Lin YJ, Cheng YC, Lee KH, Huang CC, Chen YT, et al. PrimerZ:
streamlined primer design for promoters, exons and human SNPs. Nucleic
Acids Res. 2007;35(Web Server issue):W63–65.
36. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP.
mTOR kinase structure, mechanism and regulation. Nature.
2013;497(7448):217–23.
37. Al-Owain M, Kaya N, Al-Zaidan H, Al-Hashmi N, Al-Bakheet A, Al-Muhaizea
M, et al. Novel intragenic deletion in OPHN1 in a family causing XLMR
with cerebellar hypoplasia and distinctive facial appearance. Clin Genet.
2011;79(4):363–70.
38. Shang YC, Chong ZZ, Wang S, Maiese K. Erythropoietin and Wnt1
govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.
Curr Neurovasc Res. 2011;8(4):270–85.
39. Smrz D, Kim MS, Zhang S, Mock BA, Smrzova S, DuBois W, et al. mTORC1
and mTORC2 differentially regulate homeostasis of neoplastic and
non-neoplastic human mast cells. Blood. 2011;118(26):6803–13.
Mroske et al. BMC Medical Genetics  (2015) 16:102 Page 10 of 11
40. Halova I, Draberova L, Draber P. Mast cell chemotaxis - chemoattractants
and signaling pathways. Frontiers Immunology. 2012;3:119.
41. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. Activation and function of the
mTORC1 pathway in mast cells. J Immunol. 2008;180(7):4586–95.
42. Theoharides TC. Is a subtype of autism an allergy of the brain? Clin Ther.
2013;35(5):584–91.
43. Angelidou A, Francis K, Vasiadi M, Alysandratos KD, Zhang B, Theoharides A,
et al. Neurotensin is increased in serum of young children with autistic
disorder. J Neuroinflammation. 2010;7:48.
44. Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L,
Curry CJ, et al. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet.
2013;93(1):158–66.
45. Sellitto C, Li L, Gao J, Robinson ML, Lin RZ, Mathias RT, et al. AKT activation
promotes PTEN hamartoma tumor syndrome-associated cataract
development. J Clin Invest. 2013;123(12):5401–9.
46. NHLBI Exome Sequencing Project (ESP). Exome Variant Server.
(http://evs.gs.washington.edu/EVS/) Accessed Sep, 2015.
47. Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, Mizushima N, et al.
Isolation of hyperactive mutants of mammalian target of rapamycin.
J Biol Chem. 2008;283(46):31861–70.
48. Exome Aggregation Consortium (ExAC). Broad Institute, Cambridge, MA.
(http://exac.broadinstitute.org) Accessed Sep, 2015.
49. Smith LD, Saunders CJ, Dinwiddie DL, Atherton AM, Miller NA, Soden SE,
et al. Exome Sequencing Reveals De Novo Germline Mutation of the
Mammalian Target of Rapamycin (MTOR) in a Patient with Megalencephaly
and Intractable Seizures. J Genomes Exomes. 2013;2:63–72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mroske et al. BMC Medical Genetics  (2015) 16:102 Page 11 of 11
